For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | - | 0 | - | - |
| General and administrative | 3,901 | 14,300 | 1,800 | 28,816 |
| Professional fees | 4,081 | 4,081 | 11,145 | 54,523 |
| Total operating expenses | 7,982 | 18,381 | 12,945 | 83,339 |
| Loss from operations | -7,999 | -18,381 | -12,945 | -83,339 |
| Loss before provision for income taxes | -7,999 | -18,381 | -12,945 | -83,339 |
| Provision for income taxes | - | 0 | - | - |
| Net loss | -7,999 | -18,381 | -12,945 | -83,339 |
| Earnings per share, basic | - | 0 | 0 | 0 |
| Weighted average number of shares outstanding, basic | - | 1,026,406,001 | 1,026,371,000 | 1,018,519,500 |
| Earnings per share, diluted | 0 | 0 | 0 | 0 |
| Weighted average number of shares outstanding, diluted | 1,039,836,001 | 1,026,406,001 | 1,026,371,000 | 1,018,519,500 |
NIKA PHARMACEUTICALS, INC (NIKA)
NIKA PHARMACEUTICALS, INC (NIKA)